For example, MEDI0382, a synthetic palmitoylated dual agonist of GLP-1R and GCGR derived from oxyntomodulin, achieved both significant weight loss and blood glucose lowering effects in obese and T2D patients during phase 2 trials (Ambery et al., 2018). This evidence concerns the gene GLP1R and type 2 diabetes mellitus.